ReutersReuters

Karolinska Development's Modus Therapeutics Gets Approval For 2nd Part Of Phase 2 Study

RefinitivLess than 1 min read

Karolinska Development AB KDEV:

  • REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY MODUS THERAPEUTICS RECEIVES APPROVAL FOR SECOND PART OF PHASE 2 STUDY IN CHRONIC KIDNEY DISEASE WITH ANEMIA

Login or create a forever free account to read this news